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Ricard Mesia2,3,9† and Vickie Baracos10†
1 Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain, 2 Bellvitge
Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain, 3 Head and Neck Cancer Unit, Bellvitge
University Hospital, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain, 4 University of
Barcelona, Barcelona, Spain, 5 Medical Oncology Department, Catalan Institute of Oncology (ICO), ONCOBELL, L’Hospitalet
de Llobregat, Barcelona, Spain, 6 Unitat de Nutrició Clı́nica i Dietètica, Hospital Universitari Germans Trias i Pujol (HUGTiP),
Barcelona, Spain, 7 Unitat de Bioestadı́stica (UBiDi), Bellvitge University Hospital, L’Hospitalet de Llobregat, Barcelona, Spain,
8 Grupo Ascires, CETIR Grupo Médico, Barcelona, Spain, 9 Medical Oncology Department, Catalan Institute of Oncology
(ICO)-Badalona, B-ARGO group, Barcelona, Spain, 10 Division of Palliative Care Medicine, Department of Oncology,
University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
Background: Reduced muscle mass has been associated with increased treatment
complications in several tumor types. We evaluated the impact of skeletal muscle index
(SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/
metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune
checkpoints inhibitors (ICI).
Methods: A single-institutional, retrospective study was performed including 61
consecutive patients of R/M HNSCC diagnosed between July 2015 and December
2018. SMI was quantified using a CT scan at L3 to evaluate body composition. Median
baseline SMI was used to dichotomize patients in low and high SMI. Kaplan-Meier
estimations were used to detect overall survival (OS) and progression-free survival (PFS).
Toxicity was recorded using Common Terminology Criteria for Adverse Event v4.3.
Results: Patients were 52 men (85.2%) with mean of age 57.7 years (SD 9.62), mainly
oral cavity (n = 21; 34.4%). Low SMI was an independent factor for OS in the univariate
(HR, 2.06; 95% CI, 1.14–3.73, p = 0.017) and multivariate Cox analyses (HR, 2.99; 95%
CI, 1.29–6.94; p = 0.011). PFS was also reduced in patients with low SMI (PFS HR, 1.84;
95% CI, 1.08–3.12; p = 0.025). IrAEs occurred in 29 (47.5%) patients. There was no
association between low SMI and IrAEs at any grade (OR, 0.56; 95% CI, 0.20–1.54; p =
0.261). However, grades 3 to 4 IrAEs were developed in seven patients of whom three
had low SMI.June 2021 | Volume 11 | Article 6996681
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Frontiers in Oncology | www.frontiersin.orgConclusions: Low SMI before ICI treatment in R/M HNSCC patients had a negative
impact on OS and PFS. Further prospective research is needed to confirm the role of body
composition as a predictive biomarker in ICI treatment.Keywords: head and neck (H&N) cancer, body composition, muscle mass, immune checkpoint inhibitors,
sarcopenia, immune-related adverse events (irAE)INTRODUCTION
Among patients with head and neck squamous cell carcinoma
(HNSCC), between 5% and 10% are diagnosed with metastatic
disease. Additionally, despite aggressive multimodal strategies,
about 60% of patients treated with radical intention for a locally
advanced disease will eventually recur (1). Until the introduction
of immunotherapy agents, the median survival was 10.1 months,
with an 82% rate of grades 3 to 4 adverse events using the historic
standard first-line EXTREME (combining platinum and 5-
fluorouracil (5-FU) and cetuximab) (2). Patients with
progressive disease after platinum-based chemotherapy have a
poor prognosis with a 1-year survival under 5% (3). Hereby,
there is an urgent need for improved therapy in the recurrent and
metastatic (R/M) population.
Targeting the programmed cell death (ligand)-1 (PD-(L)1)
pathway has shown significant activity, and improved overall
survival (OS) in patients with previously treated R/M HNSCC,
associated with fewer grades 3 or 4 toxicities than standard
therapy (4, 5). These results have led to approval of two anti-PD1
agents (pembrolizumab and nivolumab) as second-line
treatment for patients with R/M HNSCC who experience
disease progression on or after a platinum-based therapy (6, 7).
More recently, pembrolizumab has been approved in the first-
line setting, alone or in combination with chemotherapy (8).
Despite improving the results compared with older strategies,
approximately 70% of patients do not benefit from immune
checkpoint inhibitors (ICI) as they have progression as the best
response, enhancing the need for predictive biomarkers (6, 8).
Patients with R/M HNSCC are at an increased nutritional
risk, and malnutrition has been shown to be an independent
indicator of prognosis in cancer patients (9). The nutritional
deterioration of HNSCC patients is often present from diagnosis
and worsens throughout onco-specific treatments (10). This
deterioration does not only occur exclusively at the expense of
weight alone but also because the loss of muscle mass has been
shown to associate with prognosis and complications (10, 11).
Sarcopenia, defined as a reduced skeletal muscle mass that
reduce muscle function, is noted in geriatric populations (12).
Reduced muscle mass is also prominent in patients at any age
with different chronic diseases, including cancer. This is also
termed sarcopenia, and it is typically classified in relation to the
risk of disease-specific outcomes, such as mortality, surgical
complications, or cancer treatment (13). Sarcopenia has been
reported to have a significant impact on both OS and
complications in cancer patients undergoing onco-specific
treatment and/or surgery (14). These results have also been
described in head and neck cancer patients (15–18). Although2
some studies have revealed that low muscle mass may also have a
role in the oncological outcomes in patients with melanoma (19,
20) or lung cancer (21, 22) treated with ICI, as far as we know,
there are no current studies evaluating the impact of low muscle
mass in R/M HNSCC undergoing these therapies.
We aim to evaluate the muscle mass as a predictive biomarker
of OS and progression-free survival (PFS) in patients diagnosed
with R/MHNSCC treated with ICI. A secondary analysis focused
on the association of muscle mass on the onset of immune-
related adverse events (IrAES).MATERIALS AND METHODS
Population and Study Design
This longitudinal retrospective single-center study was approved
by the local ethics committee for clinical research (PR302/18).
All patients provided written informed consent. Patients
diagnosed with R/M HNSCC treated with ICI, regardless of
treatment line, from July 2015 and December 2018 at the Catalan
Institute of Oncology, were evaluated. Patients were eligible if
they had R/M HNSCC and were treated with ICI including anti-
PD1 or anti-PDL1 alone or in combination with other ICI (such
as anti-CTLA4) or chemotherapy and had a staging full-body
computed tomography (CT) scan as part of their pre-treatment
procedure (within 10 days prior to the introduction of ICI) and
at evaluation of tumor response according to RECIST criteria,
version 1.1 (23).
Clinical data included age, sex, smoking status, alcohol
consumption, Eastern Cooperative Oncology Group
Performance Status (ECOG-PS), TNM on Cancer (7th edition)
(24), primary tumor site, treatment line for R/M disease, type of
recurrence prior ICI, and response. Those patients, who had
received the last dose of platinum 6 months before of initiation of
ICI, were classified as platinum-refractory. Additional
information regarding IrAEs according to the CTCAE version
4.3 2009 (25) and vital status were also collected from
medical records.
Nutritional data were collected at baseline (before starting
treatment). These data included body mass index (BMI
calculated as [(weight (kg)/height (m2)], serum albumin levels,
and type of nutritional intervention if any.
Image Analysis
All treatment images were selected by a trained researcher to
ensure they correspond to the same vertebra landmarks to allow
a proper comparison of body composition. Values were obtained
by a single observer blinded to the patients’ data.June 2021 | Volume 11 | Article 699668
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patients had an abdominal CT scan as part of their routine care.
The third lumbar (L3) vertebra was chosen on the axial cross-
section CT component of the full-body CT scans as the
reference point, based on previous reports with this level to
calculate the skeletal muscle index (SMI) (26, 27) using
SliceOmatic© software (v5.0 Rev 8, Tomovision, Montreal,
Quebec, Canada). Regional analysis at L3 strongly predicted
whole-body fat and fat-free mass (r=0.86-0.94; p < 0.001) (26).
Muscle cross-sectional area (CSA) was quantified within a
Hounsfield unit (HU) range from -29 to +150HU and then
normalized for height to report as SMI (cm2/m2). Sarcopenia
was defined according to Martin L et al. (28) using specific SMI
cut points for advanced cancer patients. CSA of adipose tissue
were determined using tissue-specific HU range defined at this
level (29).
Statistical Analysis
To define cohort characteristics, categorical variables were
presented as the number of cases and percentages, whereas
continuous variables were presented as the mean and standard
deviation (SD) or median and interquartile range (IQR). Median
baseline SMI was used to dichotomize patients in two groups:
low SMI (patients with baseline SMI lower than median baseline
SMI) or high SMI (patients with baseline SMI equal or higher
than median baseline SMI).
It was planned to test for the effect of baseline SMI on
survival. Time between treatment initiation and disease
progression or death from any cause (PFS) and time between
treatment initiation and death from any cause (OS) was assessed
using the Kaplan-Meier estimator. One-year OS rate and 1-year
PFS rate were also analyzed. The Cox proportional hazards
model was used to perform univariate and multivariate
survival analyses, which are reported as the hazard ratio (HR)
and 95% confidence interval. Covariates with a p-value lower
than 0.1 in the univariate model were included in the
multivariate models. The proportionality of risks in the Cox
model was verified using the Schoenfeld residuals.
To evaluate the effect of baseline variables in the development
of toxicity, logistic regression models were used. Odds ratios and
their corresponding 95% confidence intervals were derived from
both univariate and multivariate models.
Statistical significance was set at a probability level ≤0.05. The
statistical package used to treat the data and perform the
statistical analysis was R software version 3.5.RESULTS
Patient Characteristics
Table 1 shows base l ine demographic and cl in ica l
characteristics of the 61 patients included in the analysis.
Most patients were male (n = 52, 85.2%) with a mean age of
57.7 years (SD 9.62). Tumor location was mainly oral cavity
(n = 21; 34.4%). Most of patients recurred with locoregional
plus metastatic disease (n = 28; 45.9%). Four (6.5%) patientsFrontiers in Oncology | www.frontiersin.org 3received ICI as the first treatment and 59% (n = 36) were
platinum refractory.
At baseline, the mean BMI was 23.8 kg/m2 (SD 4.56);
underweight (BMI ≤18.5) was present in 9 (14.8%) patients and
26 (42.6%) were overweight (BMI ≥25) or obese (BMI ≥30). Median
SMI was 42.0 cm2/m2 (IQR 37.5; 48.6) and was used to classify
patients between high and low SMI. Nutritional support was
required in 34 (55.7%) patients, 15 (44.1%) of them needed a
tube feeding. Two thirds (n=41, 67.2%) of the patients were
sarcopenic according to previously published cut points (30) and
three of them were also obese (Table 1S, Supporting Information).
Significant differences were identified for patients with low vs
high SMI in mean age (p = 0.035), baseline weight (p < 0.001),
BMI (P < 0.001), and total adipose tissue (p = 0.003). Patients
with high SMI were older, heavier, and with higher BMI. No
other significant differences between patients with low and high
SMI at baseline were found.
Effects of SMI in Overall Survival (OS) and
Progression Free Survival (PFS)
Median follow-up time was 9 months (range, 3.6–21.3). Up to a
third of patients (n=16; 26.2%) were alive at last follow-up. The
median time to death was 4.3 months (range, 2.3–10.9). Table 2
summarized univariate and multivariate analyses of OS, PFS, 1-
year survival, and 1-year PFS.
Patients with low SMI had shorter OS (HR, 2.06; 95% CI,
1.14–3.73; p = 0.017) (Figure 1) and 1-year OS rate (HR, 2.64;
95% CI, 1.33–5.23; p = 0.005) in the univariate analysis. Low SMI
was also associated with global PFS (global PFS HR, 1.84; 95% CI,
1.08–3.12; p = 0.025, and 1-year PFS rate HR, 1.83; 95% CI, 1.01–
3.23; p = 0.036) among other factors such as age (PFS HR, 0.96;
95% CI, 0.94–0.99; p = 0.002), baseline albumin (PFS HR, 0.95;
95% CI, 0.91–0.99; p = 0.027), platinum-refractory (PFS HR,
3.04; 95% CI, 1.67–5.56; p = <0.001), and any number of prior
lines for R/M disease (PFS HR, 1.94; 95% CI, 1.09–3.46; p =
0.025). The association was maintained at 1-year PFS, although
the number of prior lines showed only a trend (PFS HR, 1.71;
95% CI, 0.93–3.16; p = 0.084). One-year PFS showed a clear
association with age (PFS HR, 0.97; 95% CI, 0.94–1.00; p =
0.036), serum albumin (PFS HR, 0.94; 95% CI, 0.90–0.99; p =
0.025), low SMI (PFS HR, 2.53; 95% CI, 1.19–5.37; p = 0.015),
and patients who received platinum within 6 months prior to ICI
(PFS HR, 3.57; 95% CI, 1.50–8.51; p = 0.004).
The multivariate analyses adjusted for serum albumin,
baseline SMI, and platinum-refractory confirmed low SMI as
an independent predictor for OS (HR, 2.19; 95% CI, 1.19–4.05;
p = 0.012) and 1-year survival (HR, 2.79; 95% CI, 1.37–5.67; p =
0.005) adjusting this analysis also for age. Type of recurrence
prior ICI initiation and BMI were not included in the
multivariate analysis because it did not show association for
survival or PFS in the univariate analysis.
Similar results were found using previously published cut
points for sarcopenia (28) for OS but not for PFS. These results
showed that sarcopenia was an independent factor for OS (HR,
2.06; 95% CI, 1.01–4.23; p = 0.048) after adjusting by the same
covariates than the analysis performed for low SMI. This analysisJune 2021 | Volume 11 | Article 699668
Arribas et al. Muscle Mass in Immune Checkpoints Inhibitorsis provided as Supplementary Information (Table 2S
and Figure 1S).
We sought to determine whether different BMIs
were associated with any of the abovementioned outcomes.Frontiers in Oncology | www.frontiersin.org 4There were no statistically significant differences in
OS and PFS, when examining overweight or obese
patients (BMI ≥ 25 kg/m2) compared with patients with
normal BMI.TABLE 1 | Patient baseline characteristics (overall and according to low vs high skeletal muscle index) (SMI) (n=61).
Overall (n=61) Low SMI (n=30) High SMI (n=31) p-overall
Age, years
Mean (SD) 57.7 (9.62) 55.1 (9.93) 60.3 (8.73) 0.035
Median (range) 59.0 (23-78) 55.9 (23-70) 61.3 (35-78) 0.753
Male, n (%) 52 (85.2) 24 (80.0) 28 (90.3) 0.301
Smoking status, n (%) 0.394
Current 28 (45.9) 16 (53.3) 12 (38.7)
Former* 26 (42.6) 12 (40.0) 14 (45.2)
Never 7 (11.5) 2 (6.7) 5 (16.1)
Alcohol consumption#, n (%)
Yes 36 (59.0) 19 (63.3) 17 (54.8) 0.699
Location, n (%) 0.283
Oral cavity 21 (34.4) 11 (36.7) 10 (32.3)
Hypopharynx 8 (13.1) 5 (16.7) 3 (9.7)
Larynx 19 (31.3) 6 (20.0) 13 (41.9)
Oropharynx** 13 (21.3) 8 (26.7) 5 (16.1)
Type of recurrence 0.700
Locoregional 23 (37.7) 10 (33.3) 13 (41.9)
Distance 10 (16.4) 6 (20.0) 4 (12.9)
Locoregional + distance 28 (45.9) 14 (46.7) 14 (45.2)
Line of therapy, n (%) 0.865
First 22 (36.1) 10 (33.3) 12 (38.7)
Second or above 39 (63.9) 20 (66.7) 19 (61.3)
Type of ICI therapy, n (%) 0.786
AntiPD1 8 (13.1) 5 (16.7) 3 (9.7)
AntiPD1+virus 1 (1.64) 0 (0.0) 1 (3.3)
AntiPD1 + chemotherapy 3 (4.92) 2 (6.7) 1 (3.2)
AntiPDL1 12 (19.7) 5 (16.7) 7 (22.6)
AntiPDL1+antiCTLA4 22 (36.1) 11 (36.7) 11 (35.5)
AntiPDL1+IOA 15 (24.6) 9 (29.0) 6 (20.0)
ECOG-PS, n (%) 0.363
0 1 (1.64) 0 (0.0) 1 (3.2)
1 58 (95.1) 30 (100) 28 (90.3)
2 2 (3.28) 0 (0.0) 2 (6.5)
Platinum within 6 months of ICI,n (%) 36 (59.0) 18 (60.0) 18 (58.1) 1.000
Weight, kg
Mean (SD) 67.3 (15.0) 59.5 (10.9) 74.9 (14.7) <0.001
Median [Q1; Q3] 65.2 [54.3;79.0] 58.8 [51.0;65.6] 77.5 [64.3;84.5] <0.001
BMI, kg/m2
Mean (SD) 23.8 (4.56) 21.3 (3.33) 26.2 (4.32) <0.001
Median (range) 23.6 (15.8-34.7) 21.7 (15.8-27.6) 26.8 (17.7-34.6) <0.001
BMI categorized, kg/m2 0.001
Underweight (<18.5) 9 (14.8) 7 (23.3) 2 (6.5)
Normal (18.5 – 25) 26 (42.6) 17 (56.7) 9 (29.0)
Overweight /obese (>25) 26 (42.6) 6 (20.0) 20 (64.5)
Albumin, g/L
Mean (SD) 42.9 (60.3) 43.0 (3.24) 42.9 (7.86) 0.933
Median [Q1; Q3] 44.0 [41.0;46.0] 43.0 [41.0;45.0] 44.0 [42.0;46.5] 0.302
SMI, cm2/m2
Mean (SD) 43.6 (7.75) 37.2 (3.14) 49.8 (5.44) <0.001
Median [Q1; Q3] 42.0 [37.5;48.6] 37.5 [35.2;39.6] 48.6 [46.1;53.0] <0.001
TATI, cm2/m2
Mean (SD) 91.4 (53.3) 71.7 (44.5) 111 (54.7) 0.003
Median [Q1; Q3] 98.8 [49.4;118] 70.8 [31.5;101] 112 [82.0;148] 0.004June 2021 | Volume 11 | Artic*Ex-smoker defined as no cigarettes for more than 6 months before diagnosis.
#Alcohol consumption defined as sustained heavy drinker (≥4 drinks per week in women and ≥5 drinks per week in men). Includes active and former drinkers.
ICI, immune checkpoint inhibitor; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; BMI, body mass index; SMI, skeletal muscle index; TATI, total adipose tissue
index; IOA, immuno-oncology agent.
**3 of them HPV-related.le 699668
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IrAEs occurred in 29 (47.5%) patients mainly in those treated
with anti-PDL1 plus IOA (n = 15; 80%) and treated with anti-
PD1 plus chemotherapy (n = 2; 66.7%). Thyroiditis, skin, and
liver alterations were the most common IrAEs, and the vast
majority was grade 1 or grade 2. Only seven patients developed
grade 3 or above toxicity, three of them with low SMI.
There was no association with low SMI and IrAEs of any
grade (OR, 0.56; 95% CI, 0.20–1.54; p = 0.261).
Different factors were examined to determine their effect in
the development of IrAEs. Patients with BMI ≤18.5 kg/m2 (OR,
0.09; 95% CI, 0.00–0.63; p = 0.012), the presence of distance
metastasis (OR, 4.93; 95% CI, 1.01–30.4, p = 0.048), and those
patients platinum-refractory (OR, 0.33; 95% CI, 0.11–0.94,
p = 0.037) were associated with toxicity of any grade. In the
multivariate analysis, only being refractory to platinum (OR,
2.88; 95% CI, 1.05–8.98, p = 0.050) was a predictive factor of
IrAEs occurrence. The presence of distant metastasis was not
included in the multivariate analysis because only three patients
with distant metastasis did not develop IrAEs.DISCUSSION
Immunotherapy is significantly changing the therapeutic
landscape for R/M HNSCC (4, 5). Its clinical efficacy varied
among HNSCC patients, and there is a lack of accurate and
effective predictive biomarkers. Low SMI is frequently
encountered in HNSCC patients (10, 16). However, whether
low SMI can be used as a predictive biomarker for ICI remains
unknown, and the clinical data regarding the association between
SMI and ICI efficacy are quite limited. To the best of ourFrontiers in Oncology | www.frontiersin.org 5knowledge, this is the first study to assess the association
between SMI and clinical outcomes of R/M HNSCC patients
undergoing ICI therapy.
In our study, low SMI was confirmed to be an independent
factor for reduced OS and 1-year survival after adjusting the model
for relevant factors associated with clinical outcomes in HNSCC.
These findings are in agreement with other studies performed in
melanoma and lung cancer (19, 31). We did not assess mortality
specific for cancer as only two patients died from another cause
different from the primary cancer. Important variables such as age,
serum albumin, refractoriness to platinum or the number of lines
of therapy prior to ICI therapy are well-known predictive factors.
However, body composition is often overlooked in clinical
practice. BMI is not a good indicator of body composition as
elevated BMI may hide a distribution of low muscle mass
increasing the risk for adverse outcomes (19, 32). Moreover,
muscle has been shown to be one of the strongest parameters
associated with mortality in cancer patients (33) even when weight
and BMI are included in the analysis.
There are numerous cut points values published for sarcopenia
although none of them is yet definitive. Some of these cut points
used OS as the outcome according to the SMI (27, 30). We have
chosen Martin et al. (30) as their population is a large sample with
advanced stage and includes all BMIs. Moreover, these cut points
have been used in many previous publications, so readers can
compare our results. As our cohort is a slightly distinct population,
we also chose the median L3 SMI cut point to evaluate SMI as a
predictive biomarker in R/M HNSCC.
Although the mechanism by which reduced SMI has a
negative effect on the clinical efficacy of ICI remains unclear.
New evidence shows that skeletal muscle cells, as an endocrine
organ, may secrete specific cytokines that regulate immunity.TABLE 2 | Univariate and multivariate analysis examining OS, one-year survival, global PFS and one-year PFS in association with skeletal muscle index (SMI) (n=61).
SURVIVAL PROGRESION FREE SURVIVAL
Overall survival 1-year survival Global PFS 1-year PFS
Univariate analysis
HR 95% IC P value HR 95% IC P value HR 95% IC P value HR 95% IC P value
BMI 0.97 0.91;1.04 0.432 0.96 0.89;1.03 0.232 0.96 0.91;1.02 0.237 0.96 0.90;1.03 0.235
Age 0.98 0.96;1.01 0.177 0.98 0.95;1.00 0.077 0.96 0.94;0.99 0.002 0.96 0.94;0.99 0.002
Serum albumin 0.97 0.93;1.00 0.056 0.97 0.93;1.01 0.112 0.95 0.91;0.99 0.027 0.95 0.90;0.99 0.024
Low skeletal muscle index 2.06 1.14;3.73 0.017 2.64 1.33;5.23 0.005 1.84 1.08;3.12 0.025 1.83 1.01;3.23 0.036
Platinum-refractory 1.76 0.94;3.28 0.075 1.85 0.91;3.78 0.089 3.04 1.67;5.56 <0.001 2.95 1.57;5.55 0.001
Type of recurrence
Distance 0.86 0.35;2.11 0.748 0.77 0.28;2.15 0.625 0.80 0.36;1.77 0.582 0.71 0.28;1.78 0.466
Locorregional + distance 1.16 0.61;2.22 0.651 1.08 0.53;2.19 0.830 1.03 0.58;1.83 0.929 1.11 0.61;2.02 0.736
Line of therapy 2 or above 1.26 0.68;2.34 0.470 1.21 0.60;2.41 0.596 1.94 1.09;3.46 0.025 1.71 0.93;3.16 0.084
Multivariate analysis* HR 95% IC P value HR 95% IC P value HR 95% IC P value HR 95% IC P value
Age 0.99 0.96;1.02 0.359 # # # 0.97 0.94;1.00 0.026
Serum albumin 0.96 0.93;1.00 0.052 0.96 0.93;1.00 0.082 # # # 0.94 0.90;0.99 0.016
Low skeletal muscle index 2.19 1.19;4.05 0.012 2.79 1.37;5.67 0.005 # # # 1.90 1.04;3.48 0.037
Platinum-refractory 1.74 0.92;3.30 0.090 1.73 0.84;3.56 0.138 # # # 3.31 1.40;7.83 0.006
Line of therapy 2 or above # # # 0.68 0.30;1.53 0.349June 2021 | Volume 11 | ArticleOS, overall survival; PFS, progression free survival; BMI, body mass index; ICI, immune checkpoint inhibitors; Type of recurrence includes locorregional disease, distance disease and
locorregional+distance disease; Line of therapy includes first vs second or above lines.
*Adjusted for the covariates with p-value <0.1 in the univariate analysis.
#Multivariate models for global PFS were not computed due to the small numbers of patients in the no-event group.699668
Arribas et al. Muscle Mass in Immune Checkpoints InhibitorsThese myokines are involved in modulating the immune
response (34). Thus, a reduction in muscle mass may have a
deleterious effect on the anti-tumor response mediated by the
immune system, following in immunosuppression (35). A
decrease in myokines due to the loss of muscle mass could
suppress tumor response to ICI, resulting in the immune escape
of tumor cells (36, 37). Inflammation also plays an important
role in the loss of muscle mass (38). All these factors may
contribute to the impairment of the antitumor immune
response to ICI in HNSCC.
We did not find any statistically significant associations
between BMI and clinical outcomes to ICI. Young et al. (19)
identified trends toward worse outcomes in patients with high
BMI and low muscle mass in patients with melanoma treated
with anti-PD1. However, we included only six patients with
BMI ≥ 25 kg/m2 and low SMI.Frontiers in Oncology | www.frontiersin.org 6Compared with traditional treatments (chemotherapy or
radiotherapy), the incidence of toxicity in HNSCC patients
treated with ICI has been reduced. We explored the effect of
low SMI on the incidence of adverse event related to ICI in
HNSCC patients, finding that low SMI was not significantly
associated with the incidence of IrAEs. Evidence suggests that the
incidence of IrAEs of any grade is associated with improved
clinical outcomes (39). Unfortunately, subgroups analysis could
not be further performed because of insufficient data.
Our study has some limitations that should be addressed. The
main ones are the retrospective design of the study and the
limited number of patients. Moreover, the CT imaging analysis
was limited by the data availability; indeed, the acquisition
protocol was planned according to the presence of previous
examination. Finally, we did not take into account the type of ICI
therapy alone or in combination.A
B
FIGURE 1 | Kaplan-Meier survival curves according to baseline SMI. (A) Overall survival. (B) Progression Free Survival.June 2021 | Volume 11 | Article 699668
Arribas et al. Muscle Mass in Immune Checkpoints InhibitorsIn conclusion, our finding shows that baseline SMI is an
independent factor for survival R/M HNSCC treated with ICI.
SMI is not associated with the onset of IrAEs. Further
prospective research is needed to confirm the role of body
composition as a predictive biomarker in ICI treatment and
how SMI can affect drug-specific and organ-specific adverse
events caused by ICI in HNSCC patients.DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online
repositories. The names of the repository/repositories and
accession number(s) can be found below: IDIBELL repository
(http://diposit.ub.edu/dspace/handle/2445/172899).ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Hospital Universitari de Bellvitge Ethics Committee
for Clinical Research (PR302/18). The patients/participants
provided their written informed consent to participate in this study.AUTHOR CONTRIBUTIONS
LA, MP, MT, RM, and VB were actively involved in the design of
the stud writing the manuscript. LA, MP, MS, NV, AT, and LRFrontiers in Oncology | www.frontiersin.org 7were involved in the collection of data. NP and LA analyzed the
data and all authors interpreted the data reviewed the
manuscript. RM and VB supervised the study. All authors
contributed to the article and approved the submitted version.FUNDING
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